Publisher: Bentham Science Publishers
E-ISSN: 1875-6182|10|4|352-361
ISSN: 1871-5257
Source: Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol.10, Iss.4, 2012-12, pp. : 352-361
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Inflammation is essential for atherogenesis, and many inflammatory markers have been analyzed for their association with short- and long-term outcome in patients with manifestations of coronary artery disease. C-reactive protein (CRP) plasma levels increase in patients with acute coronary syndrome (ACS). CPR is an important prognostic marker in ACS. Although CRP will remain over time a useful marker, the role and implications of increased plasma concentrations of other acute phase proteins (APPs), such as alpha-1-antitrypsin (A1AT), alpha-1 glycoprotein (A1GP), haptoglobin (HG), ceruloplasmin (CP), and C3c and C4 complement fraction, in patients with ACS are still not completely defined. Controversy is the role of statins and other drugs on inflammatory markers. This review summarizes the experimental and clinical evidence regarding the role, and the biological and clinical significance of these APPs in ACS. Furthermore, biological and clinical significance of Pentraxin 3 (PTX3), a member of the pentraxin superfamily, are discussesed.
Related content
By Stefanadis C. Diamantopoulos L. dernellis J. Economou E. Tsiamis E. Toutouzas K. Vlachopoulos C. Toutouzas P.
Journal of Molecular and Cellular Cardiology, Vol. 32, Iss. 1, 2000-01 ,pp. :
Cardiac markers in acute coronary syndrome
Future Cardiology, Vol. 1, Iss. 4, 2005-07 ,pp. :
By Stensææth Knut Haakon Fossum Eigil Hoffmann Pavel Mangschau Arild Skretteberg Per Torger Kløøw Nils Einar
Scandinavian Cardiovascular Journal, Vol. 45, Iss. 2, 2011-04 ,pp. :